The healthcare giant is doubling down on oncology, betting that targeted therapies and data will reshape how cancer drugs reach patients.

Revolution Medicines' new pancreatic cancer treatment Rasonque carries a record annual cost, highlighting a decade-long trend of soaring oncology prices.